<DOC>
	<DOCNO>NCT02053064</DOCNO>
	<brief_summary>P2-SAF-301 open-label interventional study without administration investigational product , evaluate long-term safety tolerability intracerebral SAF-301 previously administer 4 patient Sanfilippo type A syndrome . The primary objective collect additional safety tolerability data intracerebral SAF-301 previously administer 4 patient Sanfilippo type A syndrome . The secondary objective collect data assess effect SAF-301 neurological psychological status , potential biological marker .</brief_summary>
	<brief_title>Long-term Follow-up Sanfilippo Type A Patients Treated Intracerebral SAF-301 Gene Therapy</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Patients complete previous phase I/II study ( P1SAF301 ) , Family understand followup procedure inform consent , Patient 's parent sign informed consent form . Participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Nervous system disease</keyword>
	<keyword>Genetic disease , Inborn</keyword>
	<keyword>Metabolic disease</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Adeno Associated Virus ( AAV )</keyword>
</DOC>